Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Pembrolizumab Inj bulk supplier for pharma manufacturers

Pembrolizumab Inj 25 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 25 mg/mL

Reference Brands: Keytruda (USA/EU)

Category: Oncology Cancer Care

Pembrolizumab is a humanized monoclonal antibody and an immune checkpoint inhibitor that targets the PD-1 (programmed death receptor-1) pathway. By blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), Pembrolizumab enhances T-cell mediated immune responses against cancer cells.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide

Product Description:

Pembrolizumab is an immunotherapy medication used in the treatment of various advanced and metastatic cancers. It belongs to a class of drugs known as immune checkpoint inhibitors and works by enhancing the body’s immune response against cancer cells. Pembrolizumab specifically targets the programmed death-1 (PD-1) receptor on T-cells, helping restore the immune system’s ability to recognize and attack tumor cells more effectively.

This medication is widely used for the management of several oncologic conditions, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, Hodgkin lymphoma, and certain other solid tumors. By blocking the PD-1 pathway, pembrolizumab helps prevent cancer cells from evading immune detection, making it an important advancement in modern cancer immunotherapy.

Pembrolizumab is administered by intravenous infusion under the supervision of healthcare professionals and requires careful patient monitoring due to potential immune-related side effects. In addition to its approved indications, ongoing clinical research continues to explore its use in additional cancer types and treatment combinations. As a result, pembrolizumab has become a key therapeutic option in the evolving field of cancer treatment.

Pembrolizumab Inj — third party manufacturing & bulk supply

Pembrolizumab Inj 25 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

What to include when you enquire

  • Destination market — determines which manufacturers hold the right site-level approvals
  • First order quantity and estimated annual volume
  • Whether you need a registration dossier or the product is already registered
  • Packaging, labelling and language requirements
  • Incoterms and required shelf life

Manufacturers of Pembrolizumab Inj listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.

Request a quote for Pembrolizumab Inj →
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Pembrolizumab is used to treat various types of cancer, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and certain other advanced or metastatic cancers. It helps the body’s immune system recognize and attack cancer cells.

Pembrolizumab is a humanized monoclonal antibody designed to target the programmed death-1 (PD-1) receptor on immune cells, helping restore the immune system’s ability to fight cancer.

The primary trade name of pembrolizumab is Keytruda.

Pembrolizumab is developed and manufactured by the pharmaceutical company Merck & Co. (known as MSD outside the United States).

The generic name is Pembrolizumab.

The brand name is Keytruda.

Pembrolizumab is manufactured in the United States and other global biologics manufacturing facilities operated by Merck & Co. for worldwide distribution.

Related Products

Fruquin 5 Mg (Fruquintinib)

Strength:
5 Mg

Form: Capsules

Reference Brands: Everest Bangladesh altd.

View Details
Vorinostat

Strength:
100 mg

Form: Capsules

Reference Brands: Zolinza (USA/EU), Vornat (India)

View Details
Panobinostat Lactate

Strength:
10 mg, 15 mg, 20 mg

Form: Capsules

Reference Brands: Farydak (USA/EU),

View Details
Gilteritinib

Strength:
40 mg

Form: Tablets

Reference Brands: Xospata (USA/India), LuciGil (Asia)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.